子癇前症における母体と胎児のインターフェースの分子研究。 (PREMAFE)
単細胞技術を使用した子癇前症の発症に向けた母体と胎児のインターフェースの分子研究。
Preeclampsia (PE) is a major obstetric complication with short- and long-term consequences for the mother and the fetus. Early screening tools to reduce its mortality and morbidity, as well as to prevent the life-threatening consequences are needed. Thus, the detection of women at risk of suffering PE is key to apply preventive and treatment strategies. Recently, the maternal contribution to PE based on defective decidualization that prevents the establishment of a functional maternal-fetal interface has been evidenced. The main objective of this study is to identify molecular markers or aberrant maternal-fetal cell types that can be detected early in the development of the disease in maternal-fetal interface tissue (chorionic villi + decidua) collected during gestational weeks 9 to 15. Maternal-fetal interface biopsy will be collected from women who have a recommendation for aneuploidy testing. The remaining fragment will be used for this study.
調査の概要
状態
条件
詳細な説明
The hypothesis is that those women who develop PE have impaired decidualization associated with shallow cytotrophoblast invasion during the development of the maternal-fetal interface whose molecular profile analysis at the single cell level will allow characterization of PE development prior to the onset of symptoms.
The purposed study is a biomedical, prospective, multicentre, case-control aimed to characterize the molecular profile of the maternal-fetal interface in the first trimester of pregnancy early in the development of preeclampsia using single-cell sequencing technology. Distinguishing the maternal and fetal origin of the chorionic biopsy cells, describing the maternal-fetal interface and deciphering the intercellular communications and altered pathways in PE and other obstetric complications could be suggested as a secondary outcome, as well as the characterization of the blood sample, the epigenome and metabolome of single cells or the validation of markers of the different cell types. Another objective will be to perform a molecular characterization of maternal-fetal blood and tissue samples collected at the time of delivery, with the aim of correlating the alterations detected in the first trimester with the molecular profiles at the end of pregnancy in both PE patients and controls.
Subjects will be 2084 pregnant women over the age of 18 recruited between 9 and 15 gestational weeks. Patients attending the participating referral centers for a chorionic villus biopsy due to the detection of a foetal chromosomal abnormality risk will provide the leftover chorionic biopsy sample after determination of the risk of trisomies and a peripheral blood sample for genotyping of maternal lymphocytes and circulating cRNA.
Data will be registered in an electronic Case Report Form (eCRF) specifically designed for this study. Monitoring activities and data verification will be performed during the whole study to ensure data quality, integrity and transparency.
The total estimated duration of the study is 52 months, of which the first 48 months will correspond to the recruitment period of the participants.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前：Carlos Simón, MD, PhD
研究連絡先のバックアップ
- 名前：Carla Gómez, BSc, MSc
- 電話番号：+34962938210
- メール：cgomez@fundacioncarlossimon.com
研究場所
-
-
Alicante
-
Alicante、Alicante、スペイン
- 募集
- Hospital General Universitario Dr. Balmis
-
コンタクト：
- Ana María Palacios Marqués
- 電話番号：965 93 30 00
- メール：ana.palacios.marques@gmail.com
-
-
Murcia
-
Murcia、Murcia、スペイン
- 募集
- Hospital Clinico Universitario Virgen de la Arrixaca
-
コンタクト：
- Juan Luis Delgado
- 電話番号：+34 968 36 96 74
- メール：juanluisdelgado@tokos.org
-
-
Santa Cruz de Tenerife
-
Santa Cruz de Tenerife、Santa Cruz de Tenerife、スペイン
- 募集
- Hospital Universitario de Canarias
-
コンタクト：
- Mercedes Hernández Suárez
- 電話番号：922 67 80 00
- メール：mercedes021281@hotmail.com
-
副調査官：
- Walter Plasencia Acevedo
-
-
Valencia
-
Valencia、Valencia、スペイン
- 募集
- Hospital Universitario y Politécnico La Fe
-
コンタクト：
- Rogelio Monfort Ortiz
- 電話番号：+34 961 24 40 00
- メール：monfort_isaort@gva.es
-
コンタクト：
- Beatriz Marcos Puig
- 電話番号：+34 961 24 40 00
- メール：marcos_bea@gva.es
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Pregnant women over the age of 18 recruited between 9 and 15 gestational weeks who attend the participating referral centers for a chorionic villus biopsy due to the detection of a foetal chromosomal abnormality risk.
説明
Inclusion Criteria:
- Patients whose written informed consent approved by the Ethics Committee (EC) has been obtained, after having been duly informed of the nature of the study and voluntarily accepted to participate after being fully aware of the potential risks, benefits and any discomfort involved.
- Women over the age of 18 at the time of signing the informed consent form.
- Pregnant women with a single gestation between weeks 9 and 15 of gestation who will undergo a chorionic villus biopsy according to the centre's usual clinical practice.
Exclusion Criteria:
- Women with multiple pregnancy.
- Non-evolving pregnancies (including delayed abortion/foetal orbit).
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 観測モデル：CASE_CONTROL
- 時間の展望：PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Cases group
Women recruited between 9 and 15 gestational weeks diagnosed with preeclampsia or other complication at the end of pregnancy. |
Maternal-fetal interface tissue (chorionic villi and decidua) will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in cases group. Clinical data will be compiled. |
|
Control group
Women recruited between 9 and 15 gestational weeks without diagnosis of preeclampsia or other complication at the end of the pregnancy |
Maternal-fetal interface tissue (chorionic villi and decidua) will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in control group. Clinical data will be compiled. |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To charactize the molecular profile of the maternal-fetal interface between 9 and 15 weeks of gestation in healthy and preeclamptic pregnancies
時間枠：From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks
|
Differentially expressed genes between control vs preeclampsia group at the level of cell types/subtypes |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To characterise the molecular profile of the maternal-fetal interface between 9 and 15 weeks of gestation in pregnancies diagnosed with pregnancy complication other than preeclampsia
時間枠：From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks
|
Differentially expressed genes between control vs cases group at the level of cell types/subtypes. |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks
|
|
To characterize the molecular profile of the maternal-fetal interface at the end of pregnancy in healthy and preeclamptic pregnancies
時間枠：From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks
|
Differentially expressed genes between control vs preeclampsia group at the level of cell types/subtypes |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks
|
|
To characterise the epigenome and metabolome of individual cells from the maternal-fetal interface in healthy pregnancies and those diagnosed with preeclampsia or other pregnancy complication
時間枠：From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks
|
Differentially methylation profiles and differentially metabolites between control vs cases group at the level of cell types/subtypes. |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks
|
|
The discovery and validation of molecular markers as candidates for early diagnosis and/or therapy
時間枠：From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks
|
Area Under the ROC Curve and/or cell type phenotyping in in vitro cultures after disrupting the candidate |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Tamara Garrido, PhD、Fundación Carlos Simon para la investigación en salud de la mujer
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。